Evidence map›Paper›PMID 40375964›Full record

ArticleSAGE open medical case reports2025

Successful treatment of localized scleroderma using brodalumab: A case report.

Alexandra Carla Bobica, Catherine Zhu, Catherine Silotch, Hessah BinJadeed, Elena Netchiporouk

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alexandra Carla BobicaDivision of Clinical and Translational Research, McGill University, Montreal, QC, Canada.ORCID https://orcid.org/0009-0005-0585-1546
Catherine ZhuFaculty of Medicine, McGill University, Montreal, QC, Canada.
Catherine SilotchDivision of Clinical and Translational Research, McGill University, Montreal, QC, Canada.
Hessah BinJadeedDivision of Dermatology, McGill University Health Centre, Montreal, QC, Canada.
Elena NetchiporoukDivision of Dermatology, McGill University Health Centre, Montreal, QC, Canada.ORCID https://orcid.org/0000-0002-6692-7787

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the first documented use of brodalumab, an IL-17 receptor antagonist, for treating severe linear localized scleroderma refractory to conventional therapies, including methotrexate, mycophenolate mofetil and corticosteroids. The patient demonstrated rapid and sustained improvement in disease activity and severity, highlighting the potential role of IL-17 signaling in the pathogenesis of localized scleroderma. This case supports further investigation of IL-17 pathway blockade in autoimmune fibrotic diseases.

Indexed as

brodalumabcancerimmune checkpoint inhibitorslocalized sclerodermamorphea

Identifiers

PMID40375964
PMCPMC12078985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.